During the reporting period, the net cash flow from operating activities was 65,438+0,325,292,979.33 yuan, and the net assets attributable to shareholders of listed companies at the end of 2020 were 7,528,539,476.95 yuan.
During the reporting period, the company achieved operating income of 5,023,206,300 yuan, up 35.76% year-on-year, and net profit attributable to shareholders of listed companies was 65,438+0,365,438+0,053,300 yuan, up 25.69% year-on-year.
During the reporting period, the management of the company made efforts to overcome the adverse effects caused by the COVID-19 epidemic, actively took effective measures to prevent and control the epidemic, protect the health of employees and plasma donors, ensure the production and supply of blood products such as intravenous immunoglobulin, and make contributions to the prevention and control of the COVID-19 epidemic in China. Actively do a good job in the resumption of work and production of apheresis plasma stations. By increasing the publicity of plasma donors and tapping the potential of existing plasma collection stations, the company's plasma collection volume gradually returned to normal level, ensuring the basic stability of the total plasma collection. Strengthen the management of pulp stations, and renew the licenses of 8 pulp stations in Fengqiu, hua county, Xunxian, Lushan, Hezhou, Bobai, Wulong and Tongnan on time, which laid the foundation for stabilizing the blood products business. The company pays attention to the research and development of new products and process optimization. During the reporting period, the company adopted chromatographic separation and purification process, nanofiltration membrane filtration+low pH incubation, double virus inactivation and virus removal technology to develop a new generation of intravenous immunoglobulin to obtain the notice of clinical trial; The newly developed recombinant Exendin-4-Fc fusion protein injection (indications: patients with type II diabetes mellitus, supplementing diet and exercise therapy to improve blood sugar control) has obtained the approval notice of drug clinical trial, and clinical research is being carried out as planned; The new technology developed by the company, human fibrinogen and chromatographic process, obtained the approval notice for the supplementary application of intravenous human immunoglobulin (pH4), which further improved the product yield and quality. The complex of human coagulation factor VIII and human prothrombin developed by Chongqing company has completed clinical research and has been declared for production.
During the reporting period, the company strengthened vaccine quality management, and the production and sales of vaccine products were good. * * * 23153,000 doses of influenza vaccine were issued in batches, accounting for 40. 16% of the national influenza vaccine batch, of which 20.624 million doses of tetravalent influenza virus split vaccine were issued in batches, accounting for 665,438 of the national tetravalent influenza virus split vaccine batch. Strengthen technological innovation and new product development, and steadily promote the research and development of products under research: tetanus vaccine has passed the production site inspection of the Food and Drug Audit and Inspection Center of the State Drug Administration, and tetravalent influenza virus split vaccine (children) has completed clinical trials and applied for drug registration. The continuous advancement of new product research and development has cultivated new profit growth points for the company.
During the period, the financial expenses were-10, 913,002.01yuan, which decreased by 388.05% year-on-year, mainly due to the increase of deposit wealth management income in this period. During the period, the investment income was 84,770,239.96 yuan, which was 65,438+038,636,408.4438+0 yuan in the same period of last year, a year-on-year decrease.
According to the announcement, during the reporting period, the total remuneration of directors, supervisors and senior managers was 5,368,200 yuan. Chairman and General Manager Ankang received a total of 940,000 yuan before tax, Director and Deputy General Manager Wang Qiping received a total of 640,000 yuan before tax, and Chief Financial Officer and Secretary of the Board Xie Junmin received a total of 5,654,380+million yuan before tax.
According to the disclosure in the announcement, the profit distribution plan adopted by the board of directors this time is: based on 65,438+0,824,366,726, the cash dividend 3 yuan (including tax) will be distributed to all shareholders for every 65,438+00 shares, and the bonus shares will be converted into 0 shares (including tax), instead of converting the reserve fund into share capital.
According to the data of Digging Shell Network, Hualan Bio is a national high-tech enterprise engaged in research and development, production and sales of blood products, vaccines and genetic engineering products.
Source link:/disclosure/listened/bulletin detail/index.html? 1ba 2cd 26-DFA 4-4db 4-96dc-37ee 0d 33 da 74
This article comes from Digging Shell Network.